GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cocrystal Pharma Inc (STU:8CC) » Definitions » Shiller PE Ratio

Cocrystal Pharma (STU:8CC) Shiller PE Ratio : (As of May. 23, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cocrystal Pharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cocrystal Pharma Shiller PE Ratio Historical Data

The historical data trend for Cocrystal Pharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cocrystal Pharma Shiller PE Ratio Chart

Cocrystal Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cocrystal Pharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cocrystal Pharma's Shiller PE Ratio

For the Biotechnology subindustry, Cocrystal Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Shiller PE Ratio falls into.



Cocrystal Pharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cocrystal Pharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Cocrystal Pharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.359/131.7762*131.7762
=-0.359

Current CPI (Mar. 2024) = 131.7762.

Cocrystal Pharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 10.282 100.560 13.474
201409 -5.813 100.428 -7.628
201412 -9.856 99.070 -13.110
201503 -8.007 99.621 -10.591
201506 -3.208 100.684 -4.199
201509 -3.208 100.392 -4.211
201512 -16.498 99.792 -21.786
201603 -3.233 100.470 -4.240
201606 -1.468 101.688 -1.902
201609 -0.853 101.861 -1.104
201612 -32.727 101.863 -42.338
201703 -1.234 102.862 -1.581
201706 -0.427 103.349 -0.544
201709 -0.906 104.136 -1.146
201712 2.129 104.011 2.697
201803 -0.584 105.290 -0.731
201806 -0.514 106.317 -0.637
201809 -0.617 106.507 -0.763
201812 -16.666 105.998 -20.719
201903 1.062 107.251 1.305
201906 -0.531 108.070 -0.647
201909 -0.654 108.329 -0.796
201912 -16.200 108.420 -19.690
202003 -0.543 108.902 -0.657
202006 -0.746 108.767 -0.904
202009 -0.509 109.815 -0.611
202012 -0.099 109.897 -0.119
202103 -0.403 111.754 -0.475
202106 -0.398 114.631 -0.458
202109 -0.408 115.734 -0.465
202112 1.133 117.630 1.269
202203 -0.472 121.301 -0.513
202206 -2.838 125.017 -2.991
202209 -0.707 125.227 -0.744
202212 -0.510 125.222 -0.537
202303 -0.598 127.348 -0.619
202306 -0.378 128.729 -0.387
202309 -0.384 129.860 -0.390
202312 -0.403 129.419 -0.410
202403 -0.359 131.776 -0.359

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cocrystal Pharma  (STU:8CC) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cocrystal Pharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cocrystal Pharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cocrystal Pharma (STU:8CC) Business Description

Traded in Other Exchanges
Address
19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

Cocrystal Pharma (STU:8CC) Headlines

No Headlines